pharma
Takeda to jettison non-core asset portfolio to Stada for $660 million
November 6, 2019Research and Development, Sales and Marketing Stada, Takeda, pharma
Takeda has announced it is divesting a portfolio of its over-the-counter (OTC) and prescription drug products to Stada for a …
Sandoz scores FDA approval for Neulasta biosimilar Ziextenzo to treat febrile neutropenia infection
November 6, 2019Research and Development, Sales and Marketing Amgen, FDA, Neulasta, Sandoz, Ziextenzo, pharma
The FDA has authorised the availability of Sandoz’s Ziextenzo (pegfilgrastim-bmez), a biosimilar version of Amgen’s Neulasta, it has emerged. The …
FDA approves Sanofi’s quadrivalent flu vaccine for over-65s
November 6, 2019Research and Development, Sales and Marketing FDA, Fluzone, Sanofi, flu, influenza, pharma
Sanofi’s quadrivalent influenza vaccine Fluzone High Dose has secured FDA approval in adult patients over the age of 65 for …
Redefining the value of medicines with patients at the centre
November 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda, health economics and outcomes research, market access, pharma
Liz Lewis, Head of Global Oncology Patient Value, Policy and Access at Takeda Oncology, discusses the importance and challenges of …
FDA approves RedHill Biopharma’s Talicia to combat Helicobacter pylori infection
November 4, 2019Sales and Marketing FDA, RedHill Biopharma, pharma
RedHill Biopharma is celebrating after the FDA chose to award marketing authorisation to Talicia (omeprazole magnesium, amoxicillin and rifabutin) for …
International revenue for world’s best-selling drug Humira falls 33.5% in the face of biosimilar competition
November 4, 2019Sales and Marketing AbbVie, Humira, pharma
With the release of its Q3 financial results, AbbVie confirmed that international revenues for its blockbuster therapy Humira (adalimumab) – …
China green lights first novel Alzheimer’s therapy since 2003
November 4, 2019Sales and Marketing Alzheimer's, China, Green Valley, Oligomannate, pharma
Shanghai Green Valley Pharmaceuticals has announced that its therapy Oligomannate (GV-971) has secured marketing approval from China’s National Medical Products Administration (NMPA) …
Promising Phase 3 data for Sanofi’s Toujeo secures CHMP recommendation of label expansion in type 1 diabetes
November 4, 2019Research and Development, Sales and Marketing EU, Sanofi, Type 1 diabetes, diabetes, pharma, toujeo
Sanofi took the opportunity at the International Society for Pediatric and Adolescent Diabetes 45th Annual Conference in Boston, Massachusetts to …
Current drugs are “poisoning” elderly patients due to insufficient trial data, House of Lords committee hears
November 1, 2019Medical Communications, Research and Development elderly patients, pharma, trial diversity
Elderly patients are being put at risk by prescriptions for drugs which have not been properly tested in their age …
Amgen drops $2.7bn to acquire stake in Chinese biotech in bid to expand in the region
November 1, 2019Medical Communications, Research and Development, Sales and Marketing Amgen, BeiGene, Cancer, China, deal, oncology, pharma
Amgen has signed an agreement with Chinese biotech BeiGene to acquire a 20.5% stake in the latter, in a bid …
Despite some advantages, Novartis’ Cosentyx fails to outclass Humira in active psoriatic arthritis
November 1, 2019Medical Communications, Research and Development Cosentyx, Humira, Novartis, active psoriatic arthritis, pharma
Novartis has announced new data drawn from a trial pitting Cosentyx (secukinumab) in head-to-head competition with AbbVie’s Humira (adalimumab) – …
Transactions in the pharma sector: Through the EU merger review looking-glass
October 31, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing mergers, mergers and acquisitions, pharma
With mergers and acquisitions back in full swing after a period of drought, Alec Burnside (Partner) and Delphine Strohl (Associate) …
AbbVie’s Rinvoq impresses at Phase 3 in active psoriatic arthritis sub-population
October 31, 2019Research and Development AbbVie, Rinvoq, pharma
AbbVie has unveiled new Phase 3 data on two doses of its JAK inhibitor Rinvoq (upadacitinib), showing that the therapy …
Catalyst’s lead candidate Firdapse falls short in Congenital Myasthenic Syndromes
October 31, 2019Research and Development Catalyst Pharmaceuticals, FDA, firdapse, pharma, trial failure
Catalyst Pharmaceuticals has made it known that its lead product Firdapse (Amifampridine Phosphate) fell short of its primary endpoint in …
Latest content
Five Facts about cardiovascular disease
